biotech thread - wednesday 20th february

Morning all,

Sorry for the absence in recent days, not a lot of time has been spent in front of the computer. With the number of people viewing the thread well below that of last year, I think a weekly thread may be more useful until biotech deals start to pick up again. What are your thoughts?

In saying that, what an eventful past week it has been!

BXN has announced the acquisition of sales and distribution business VITALITY, a marketing distributor of high value medical devices in Australia and other key South East Asia regions.
The initial products focus of the company is on Chronic Heart Failure and Type 2 Diabetes.

These products are already CE marked and have received reimbursement approvals in key markets including Germany and the USA. In addition, the “DIAMOND” diabetes device has received Australia’s TGA approval.

The company should come out of a trading halt today with the release of a capital raising announcement.

NRT showed the market what biotechs can do when preliminary efficacy is shown in studies, closing up over 200%.

The study was designed to test the ability of the experimental anti-cancer drug, CS-6, to kill ovarian cancer stem cells. The company's CEO said the drug showed "potent" activity against cancer cells but more importantly, cancer stem cells.

Traditional treatments such as chemotherapy have no effect on these cells which are thought to contribute to relapse in patients.

It wouldn't be a biotech thread without mentioning Twinvest's baby, ADO. The company announced it has entered into a Sales Partnership Program with One World Lab Inc. OWL will provide ADO’s Mix&Go surface chemistry products to its growing base of academic and industry researchers.

OWL is a San Diego based company whose business model is to supply small quantities of antibodies and complimentary reagents to researchers worldwide giving them the opportunity to quickly test products from various suppliers and identify the reagents best suited for their work.

Although the financial details were withheld, it points to what could hopefully be an active period for holders as the company ramps up its commercialisation efforts.

Finally, the 2013 biotech tipping comp has a new leader, vogliobene, on $45,403. A 50% gain is a solid effort in any market so good work.

Have a great day,
Hammer